|제목||BioMolecular Therapeutics signs research contract with Samyang Inc. on RNAi trigger development|
BioMolecular Therapeutics signs research contract with Samyang Inc. on RNAi trigger development
BioMolecular Therapeutics, Inc. (BMT), a Korean biopharmaceutical company with proprietary RNAi trigger technology, announced today that it started a research project for Samyang Inc. for RNA interference (RNAi) therapeutics development (Research title: “optimization of asiRNA and in vitro & in vivo validation”).
BMT holds “asymmetric siRNA (asiRNA)” technology, an alternative RNAi trigger to conventional small interfering RNA (siRNA). Although the commonly used conventional siRNA molecules efficiently trigger target gene silencing, recent studies revealed that the conventional RNAi triggers evoke several non-specific effects including activation of innate immune response through the Toll-like receptor 3 (TLR3). Especially, the discovery of the non-specific activation of TLR3 by siRNAs is of concern and led to the termination of clinical trials targeting AMD. Therefore, the next generation RNAi technology with alleviated non-specific effects is considered to be crucial for the successful development of RNAi therapeutics.
asiRNA technology, one of the core technologies of BMT, significantly reduces the undesired non-specific effects triggered by conventional siRNA. Based on the asiRNA technology, BMT is pursuing internal R&D programs to develop an RNAi –based medicine and also offering research collaborations. The company is currently collaborating with Prof. Jayakrishna Ambati’s group at University of Kentucky Medical Center to develop RNAi therapeutics for age-related macular degeneration (AMD) treatment.
Dr. Dong-ki Lee, founder of BMT, Inc and Professor at Sungkyukwan University, said: ”This agreement is an important external validation of our efforts to develop the asiRNA technology. The collaboration with Samyang enables us to advance this technology to the next level. We look forward to collaborating with the Samyang team.”
About BioMolecular Therapeutics, Inc. (www.bmtlab.co.kr)
Established in 2010, BMT is a Korean biotechnology start-up company focusing on RNAi therapeutics development. BMT is pioneering the development of novel RNAi therapeutics based on the company's proprietary technology, asymmetric shorter-duplex siRNA (asiRNA). asiRNA technology has been shown to reduce undesired non-specific effects triggered by the conventional siRNA structure. Currently, BMT is developing RNAi medicine for the treatment of age-related macular degeneration, a disease to which RNAi therapeutics could not be developed using conventional siRNAs. BMT is also developing RNAi therapeutics for scarless wound healing. BMT is a privately held company and based in Suwon, South Korea.
For inquiries, email firstname.lastname@example.org